Eos Energy Enterprises Inc vs Johnson & Johnson — how do they compare? Eos Energy Enterprises Inc trades at $4.26 (market cap $1.54B), while Johnson & Johnson trades at $260.64 (market cap $626.09B). The key difference: Johnson & Johnson is far larger — about 406.6× Eos Energy Enterprises Inc's market cap, and Johnson & Johnson pays a 2.06% dividend while Eos Energy Enterprises Inc pays none. Which is the better fit depends on your goals.
| EOSE | JNJ | |
|---|---|---|
Market Cap | $1.54B | $626.09B |
Sector | Energy | Health |
52-Week High | $19.19 | $267.24 |
52-Week Low | $3.14 | $172.78 |
Enterprise Value | $1.88B | $654.37B |
Volume | — | 6,156,228 |
Dividend Yield | — | 2.06% |
Signals from Pluang's Aura AI — not financial advice
Eos Energy Enterprises (EOSE) trades at $4.24, up 4.69% today, showing mixed technical signals with a bullish overall rating but bearish moving averages. The company reported record Q2 2026 revenue but missed earnings expectations with a $1.20 loss per share. Financials reveal significant challenges with negative gross margins of -84.75% and net income margin of -246.76% for 2026, though revenue growth from $114M to $214M year-over-year shows scaling progress.
While analyst consensus targets $7.75 (83% upside), the stock faces substantial fundamental risks including negative profitability, shareholder litigation investigation, and high debt-to-asset ratio of 91.87%. The company's energy storage technology and growing backlog provide potential, but execution risks and cash burn require careful monitoring for investors considering this speculative growth play.
Johnson & Johnson (JNJ) trades at $261.26, down 0.21% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and recent earnings beats. Revenue grew to $94.19B in 2025, with a net income margin of 21.48%, though cash flow turned negative due to heavy investing. The company maintains a robust dividend history, with consistent payouts and a 64-year growth streak.
Outlook remains positive with a consensus price target of $284.50, offering ~9% upside. Risks include legal headwinds and patent expirations, but analyst sentiment is bullish (52.5% buy ratings). JNJ's defensive profile and pipeline strength support long-term growth, though investors should monitor debt levels, which rose to 24.06% of assets in 2025.
Trailing returns across standard periods
Latest headlines on both assets
Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →